Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT05572801
Recruiting Not applicable

NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer

NCT05572801 · tracked via the Priya Life Science Norway tracker
Sponsor
Aarhus University Hospital
Phase
Not applicable
Started
2023-08-02
Last updated
2024-08-14

Condition(s) studied

Anal Cancer

Investigational drug(s) / intervention(s)

AMR B: HPV positive ctDNA guided imaging in follow-up

AMR B: HPV positive ctDNA guided imaging in follow-up: Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure

Study summary

This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the potential for cure. This will be done by comparing the standard follow-up program with ctDNA guided imaging follow-up. Secondly, the aim is to establish early interventions against late morbidities.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with SCCA eligible for definitive (chemo)radiotherapy * ≥ 18 of years * Written and oral consent Exclusion Criteria: * Conditions that will contraindicate blood samples * Conditions that will contraindicate a PET-CT scan. * Potential lack of compliance to standard FU program and study participation.

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
Department of Oncology Herlev and Gentofte Hospital Herlev Capital Region of Denmark Recruiting
Department of Oncology, Vejle Hospital Vejle The Regions of Southern Denmark Recruiting
Aarhus University Hospital Aarhus Denmark Recruiting
Tampere University Hospital Tampere Finland Not Yet Recruiting
Turku University Hospital Turku Finland Not Yet Recruiting
Haukeland University Hospital Bergen Norway Not Yet Recruiting
Oslo University Hospital Oslo Norway Not Yet Recruiting
University Hospital of North Norway Tromsø Norway Not Yet Recruiting
St. Olav's University Hospital Trondheim Norway Not Yet Recruiting
Sahlgrenska University Hospital Gothenburg Sweden Not Yet Recruiting
Skåne University Hospital Lund Lund Sweden Not Yet Recruiting
Karonlinska University Hospital Stockholm Sweden Not Yet Recruiting
Norrlands University Hospital Umeå Sweden Not Yet Recruiting

More Aarhus University Hospital trials in Norway

A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) Recruiting

Other trials for the same condition

Anal Cancer Radiotherapy Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05572801 on ClinicalTrials.gov ↗ ← All trials in Norway